Diabetes Care in The Netherlands: - Novo Nordisk

More documents

Recommendations

Info

FurtherFurtherimprovingimprovinghealthhealth ofofpatientspatientsmaymayleadleadtotoEUREUR1.51.5-2-2 B ofB ofeconomic benefits in 2020economic benefits in 2020Reduction in cost ofcomplications:~ EUR 0.5 B• Estimated based on a combination of improved compliance and an increased reachof high quality care. Two high-level approaches result in a similar estimate– A Kaiser Permanente study shows that total medical cost of 80-100% compliantpatients are ~25 -30% lower than of patients who are 60-80% compliant– If the national average would show the same relative risk of complications as inthe DiabetesZorgBeter study, this would reduce cost of complications by morethan 30%• The combination of improved care and improved compliance may have higherpotential~ EUR 1.5 – 2 BReduction of lostproductivity:~ EUR 1.2 B• Absenteeism and presenteeism and the related cost decline in line with theexpected decline in the number of complications• Assumption is that 50% of the inflow of disabled in the workforce with diabetes,would have been able to remain active in the workforce if there would not havebeen diabetes complications• Estimate is that 50% inflow can be reduced in line with the assumed reduction inthe number of complications (~30%)Source:CBS, CBS, DiabetesZorg Beter study, UWV, UWV, Booz Booz & Company & AnalysisBooz & Company 14 November 201132Prepared for Novo Nordisk25
ContentsSummarized findings and recommendationsThe opportunity• Diabetes is a major and underestimated source of medical costs and lost productivity• Diabetes care in The Netherlands has reached a high level of quality, but there is still opportunity for further improvement• Further improving health of patients may lead to EUR 1.5-2 B of economic benefits in 2020The road• Refine economic incentives to encourage integrated care and quality improvement• Engage employers, UWV and participative care in diabetes care• Engage the patient’s social network to support self management• Introduce conditional market access models for new therapies and medication to assess behavioural impactAppendix: list of sources33
Page 6 and 7: SummaryDiabetes is a serious and de
Page 8: diabetes care. Extra compensation w
Page 11 and 12: ContentsSummarized findings and rec
Page 13 and 14: 11Diabetes is a major and underesti
Page 15 and 16: 33Further improving health of of di
Page 17 and 18: 22Recommendation 2: Engage employer
Page 19 and 20: 44Recommendation 4: Introduce condi
Page 21 and 22: Already more than 1M diabetes patie
Page 23 and 24: Costs of of complications and treat
Page 25 and 26: Number of patients reaches ~1.4M in
Page 27 and 28: Increase in lost productivity is dr
Page 29 and 30: Diabetes care clearly improved in t
Page 31 and 32: Better compliance can be stimulated
Page 33: ContentsSummarized findings and rec
Page 37 and 38: Delaying complications saves medica
Page 39 and 40: LimitedLimitedcollaborationcollabor
Page 41 and 42: Individual quality incentives are l
Page 43 and 44: Recommendation 1: Insurer should in
Page 47 and 48: Labour shortage from late nineties
Page 49 and 50: However, curative and participative
Page 53 and 54: Non-compliance leads to severe comp
Page 55: Facilitated patient networks are su
Page 58 and 59: Recommendation 3:Facilitate network
Page 62 and 63: But new medication could add a lot
Page 66: Booz & Company is a global manageme

Diabetes Care in The Netherlands: - Novo Nordisk

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?